SUMO: A (Oxidative) Stressed Protein

Redox species are produced during the physiological cellular metabolism of a normal tissue. In turn, their presence is also attributed to pathological conditions including neurodegenerative diseases. Many are the molecular changes that occur during the unbalance of the redox homeostasis. Interestingly, posttranslational protein modifications (PTMs) play a remarkable role. In fact, several target proteins are modified in their activation, localization, aggregation, and expression after the cellular stress. Among PTMs, protein SUMOylation represents a very important molecular modification pathway during "oxidative stress". It has been reported that this ubiquitin-like modification is a fine sensor for redox species. Indeed, SUMOylation pathway efficiency is affected by the exposure to oxidative species in a different manner depending on the concentration and time of application. Thus, we here report updated evidence that states the role of SUMOylation in several pathological conditions, and we also outline the key involvement of c-Jun N-terminal kinase and small ubiquitin modifier pathway cross talk

Cigarette smoke extract is a Nox agonist and regulates ENaC in alveolar type 2 cells

There is considerable evidence that cigarette smoking is the primary etiology of chronic obstructive pulmonary disease (COPD), and that oxidative stress occurs in COPD with the family of tissue nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) enzymes playing a significant role in lung pathogenesis. The purpose of this study was to determine the effects of cigarette smoke extract (CSE) on Nox signaling to epithelial sodium channels (ENaCs). Pre-treatment with diphenyleneiodonium (DPI), a pan-Nox inhibitor, prevented stimulatory effects of CSE on ENaC activity; open probability (Po) changed from 0.36 ± 0.09 to 0.11 ± 0.02; n = 10, p = 0.01 following CSE and DPI exposure. Likewise, Fulvene-5 (which inhibits Nox2 and Nox4 isoforms) decreased the number of ENaC per patch (from 2.75 ± 0.25 to 1 ± 0.5, n = 9, p = 0.002) and open probability (0.18 ± 0.08 to 0.02 ± 0.08, p = 0.04). Cycloheximide chase assays show that CSE exposure prevented α-ENaC subunit degradation, whereas concurrent CSE exposure in the presence of Nox inhibitor, Fulvene 5, resulted in normal proteolytic degradation of α-ENaC protein in primary isolated lung cells. In vivo, co-instillation of CSE and Nox inhibitor promoted alveolar flooding in C57Bl6 mice compared to accelerated rates of fluid clearance observed in CSE alone instilled lungs. Real-time PCR indicates that mRNA levels of Nox2 were unaffected by CSE treatment while Nox4 transcript levels significantly increased 3.5 fold in response to CSE. Data indicate that CSE is an agonist of Nox4 enzymatic activity, and that CSE-mediated Nox4 plays an important role in altering lung ENaC activity

Reactive oxygen species, vascular disease, and hypertension

Reactive oxygen species (ROS) influence many physiological processes including host defense, hormone biosynthesis, fertilization, and cellular signaling. Increased ROS bioavailability and altered redox signaling (oxidative stress) have been implicated in chronic diseases including atherosclerosis and hypertension. Although oxidative injury may not be the sole etiology of hypertension, it amplifies blood pressure elevation in the presence of other pro-hypertensive factors, such as salt loading, activation of the renin-angiotensin system, and sympathetic hyperactivity. Oxidative stress is a multisystem phenomenon in hypertension and involves the heart, kidneys, nervous system, and vessels. A major source for cardiovascular, renal, and neural ROS is a family of non-phagocytic NADPH oxidases, including the prototypic Nox2 homologue-based NADPH oxidase, as well as other NADPH oxidases, such as Nox1 and Nox4. Other possible sources include mitochondrial electron transport enzymes, xanthine oxidase, cyclooxygenase, lipoxygenase, and uncoupled nitric oxide synthase (NOS). Cross talk between Noxes and mitochondrial oxidases is increasingly implicated in cellular ROS production. Convincing findings from experimental and animal studies support a causative role for oxidative stress in the pathogenesis of hypertension. However, there is still no solid evidence that oxidative stress is fundamentally involved in the pathogenesis of human hypertension. Reasons for this are complex and relate to heterogeneity of populations studied, inappropriate or insensitive methodologies to evaluate oxidative state clinically, and suboptimal antioxidant therapies used. Nevertheless, what is becoming increasingly evident is that oxidative stress is important in the molecular mechanisms associated with cardiovascular and renal injury in hypertension and that hypertension itself can contribute to oxidative stress. This chapter provides a comprehensive review of the role of ROS in the (patho)physiology of vascular injury and discusses the importance of Noxes in vascular oxidative stress. Implications in experimental and human hypertension are highlighted